Neoprontosil, formerly called prontosil soluble or prontosil, is disodium sulfamidophenyl-2′-azo-7′-acetylamino-1′-hydroxynaphthalene-3′,6′-disulfonate. It is employed in a 2.5 or 5 per cent aqueous solution or in tablets. Its action on the various infective organisms in the body is similar to that of sulfanilamide (paraaminobenzenesulfonamide) but not identical. Long, Bliss and Feinstone1 assumed from results of experiments on animals that its action depends on the chemical reduction in the body. There is a relatively small amount of sulfanilamide present in the solution; on analysis neoprontosil yields only 11 grains, or 0.7 Gm., of sulfanilamide per hundred cubic centimeters of the 2.5 per cent solution.
Much has already been written on the use of sulfanilamide in the treatment of trachoma and gonococcic infections of the eye. The names of Loe,2 Rychener,3 Lian,4 Kirk, McKelvie and Hussein5 and Thygeson6 should be mentioned for the favorable results obtained in the
PATON RT. SUBCONJUNCTIVAL INJECTIONS OF NEOPRONTOSIL IN THE TREATMENT OF OCULAR INFECTIONS. Arch Ophthalmol. 1939;22(3):377–384. doi:10.1001/archopht.1939.00860090043004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.